Granulomatous eosinophilic epicarditis in the newborn. Report of three cases.

A. Moragas,Vidal Mt

1969-11-01

Abstract:

What problem does this paper attempt to address?

[Identification and Single-Cell Sequencing Analysis of Rare Tumor Cells in Malignant Pleural Effusion of Lung Cancer Patients].

Bao Jun Wu,Zhuo Wang,Yu Dong,Yu Liang Deng,Qi Hui Shi

DOI: https://doi.org/10.16288/j.yczz.18-230

2019-01-01

Abstract:Tumor heterogeneity refers to distinct genomic or phenotypic characteristics of tumor cells. Under the environmental or drug stress, tumor cells exhibit different responses, corresponding to different properties of cell proliferation, invasion, metastasis and drug resistance. In particular, a small fraction of tumor cells are capable of detaching from primary tumor sites and initiating distant metastases. Thus, tumor heterogeneity sets the basis for tumor resistance and metastasis. Traditional methods in studying tumor heterogeneity are mainly based on bulk cells from different locations in primary tumors, lacking analysis at the single-cell level and of metastatic tumor cells. This study establishes a single-cell method to study metastatic tumor cells in malignant pleural effusions of lung cancer patients. Metabolically active tumor cells in malignant pleural effusions are firstly identified with a metabolic marker 2-NBDG, a fluorescent glucose analog. These metabolically active tumor cells are confirmed to harbor the same driver oncogenic mutations by Sanger sequencing, followed by high-throughput sequencing to analyze copy number variation profiles. Our results show metastatic tumor cells in pleural effusion have the same driver mutations but different features in copy number variation patterns. The study provides new insights to understand the mechanism of tumor metastasis.
Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Zhengbo Song,Zhijian Cai,Junrong Yan,Yang W. Shao,Yiping Zhang

DOI: https://doi.org/10.21037/tlcr.2019.08.14

2019-01-01

Translational Lung Cancer Research

Abstract:BACKGROUND:Recently, plasma-derived exosomal DNA (exoDNA) has been successfully used in clinical genetic testing. However, the clinical utility of pleural effusion-derived exoDNA (PE-exoDNA) was still unknown. This study aimed to assess the feasibility of using PE-exoDNA for genetic testing in patients with advanced lung adenocarcinoma.METHODS:Twenty PE-exoDNA samples and 18 pleural effusion-derived cell-free DNA (PE-cfDNA) samples were obtained from 20 stage IV lung adenocarcinoma patients. Using targeted next-generation sequencing (NGS) of 416 cancer-relevant genes, the genomic alterations between PE-exoDNA and PE-cfDNA were identified and compared.RESULTS:NGS results showed highly similar mutation profiles between exoDNA and cfDNA, with TP53, EGFR, PKD1, and ALK as the top 4 mutated genes in both samples. A total of 304 genetic mutations were identified in 18 cfDNA samples and 276 genetic mutations were identified in 20 exoDNA samples. Forty-seven mutations from 8 genes (EGFR, ALK, KARS, BRAF, MET, PTEN, TP53, and RB1) were identified in 18 patients who had both exoDNA and cfDNA samples. Of the 47 mutations, 43 were shared between the two types of samples, yielding a concordance rate of 89.6%. Collectively, 78% of the mutations were shared between exoDNA and cfDNA samples, and this frequency increased to 94.2% when copy number variations (CNVs) were excluded from the analysis.CONCLUSIONS:In patients with advanced lung adenocarcinoma, the genetic profile of PE-exoDNA and PE-cfDNA were comparable, except for CNVs that had lower similarities between these two samples. Our findings support the clinical utility of exoDNA and could motivate further exploration of using exoDNA as an alternative source for genetic testing.
Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics

Ziming Li,Zhuo Wang,Yin Tang,Xiang Lu,Jie Chen,Yu Dong,Baojun Wu,Chunying Wang,Liu Yang,Zhili Guo,Min Xue,Shun Lu,Wei Wei,Qihui Shi

DOI: https://doi.org/10.1038/s41467-019-11808-3

IF: 16.6

2019-01-01

Nature Communications

Abstract:Accurate prediction of chemo- or targeted therapy responses for patients with similar driver oncogenes through a simple and least-invasive assay represents an unmet need in the clinical diagnosis of non-small cell lung cancer. Using a single-cell on-chip metabolic cytometry and fluorescent metabolic probes, we show metabolic phenotyping on the rare disseminated tumor cells in pleural effusions across a panel of 32 lung adenocarcinoma patients. Our results reveal extensive metabolic heterogeneity of tumor cells that differentially engage in glycolysis and mitochondrial oxidation. The cell number ratio of the two metabolic phenotypes is found to be predictive for patient therapy response, physiological performance, and survival. Transcriptome analysis reveals that the glycolytic phenotype is associated with mesenchymal-like cell state with elevated expression of the resistant-leading receptor tyrosine kinase AXL and immune checkpoint ligands. Drug targeting AXL induces a significant cell killing in the glycolytic cells without affecting the cells with active mitochondrial oxidation.
Single-cell analysis of diverse immune phenotypes in malignant pleural effusion

Zhong-Yin Huang,Ming-Ming Shao,Jian-Chu Zhang,Feng-Shuang Yi,Juan Du,Qiong Zhou,Feng-Yao Wu,Sha Li,Wei Li,Xian-Zhen Huang,Kan Zhai,Huan-Zhong Shi

DOI: https://doi.org/10.1038/s41467-021-27026-9

IF: 16.6

2021-11-18

Nature Communications

Abstract:Abstract The complex interactions among different immune cells have important functions in the development of malignant pleural effusion (MPE). Here we perform single-cell RNA sequencing on 62,382 cells from MPE patients induced by non-small cell lung cancer to describe the composition, lineage, and functional states of infiltrating immune cells in MPE. Immune cells in MPE display a number of transcriptional signatures enriched for regulatory T cells, B cells, macrophages, and dendritic cells compared to corresponding counterparts in blood. Helper T, cytotoxic T, regulatory T, and T follicular helper cells express multiple immune checkpoints or costimulatory molecules. Cell-cell interaction analysis identifies regulatory B cells with more interactions with CD4 + T cells compared to CD8 + T cells. Macrophages are transcriptionally heterogeneous and conform to M2 polarization characteristics. In addition, immune cells in MPE show the general up-regulation of glycolytic pathways associated with the hypoxic microenvironment. These findings show a detailed atlas of immune cells in human MPE and enhance the understanding of potential diagnostic and therapeutic targets in advanced non-small cell lung cancer.

multidisciplinary sciences
Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor

Xi Wang,Dainan Zhang,Xiudong Guan,Shunchang Ma,Wenjianlong Zhou,Jiayi Peng,Linhao Yuan,Yangyang Wang,Shucheng Jin,Qin Xu,Deling Li,Shengtian Wu,Guijun Jia,Chuanbao Zhang,Wang Jia

DOI: https://doi.org/10.21037/tlcr-23-107

2023-03-31

Translational Lung Cancer Research

Abstract:Background: Lung adenocarcinoma (LUAD) is the most common form of lung cancer and is often accompanied by brain metastasis (BM). The heterogeneity of the tumor renders all current conventional treatments less effective. This study aims to dissect tumor cell heterogeneity and identify potential therapeutic targets.Methods: We conducted single-cell RNA-sequencing (scRNA-seq) in 8 patients with treatment-naïve LUAD BM and included scRNA-seq data of 10 primary LUAD samples and their matched adjacent normal tissue from GSE131907 to determine the tumor cell heterogeneity.Results: Our analyses revealed tumor cells derived from brain metastases were more heterogeneous. Tumor cells from BM harbored significantly more copy number variants (CNVs), and cells of magnoid subtype were the critical source of malignant cells both in BM and the primary lung tumor. Pseudo-time trajectory analysis revealed that malignant cells had upregulated genes enriched for cell cycle and cell division. Integrated analysis of tumor cells revealed 2 distinct malignant cell clusters (cluster 4 and cluster 6) and their marker genes. The signatures identified in the single-cell profile had prognostic value in the bulk tumor profiles. Moreover, the signature of cluster 4 had significant prognostic value in predicting patients surviving longer than 3.5 years, while the signature of cluster 6 showed better predictive ability within 1 year. Magnoid-type cells are most likely to develop into the riskiest cell type and potentially promote tumor progression.Conclusions: scRNA profiling that integrates LUAD BM and primary LUAD can provide information on those malignant cells with BM potential, offering additional prognostic information at cellular level, and may serve as a foundational resource for further tumor cell dissection and therapeutic target exploration.

oncology,respiratory system
Microdissection of the Bulk Transcriptome at Single-Cell Resolution Reveals Clinical Significance and Myeloid Cells Heterogeneity in Lung Adenocarcinoma

Hao Wu,Jiale Qin,Qiang Zhao,Lu Lu,Chen Li

DOI: https://doi.org/10.3389/fimmu.2021.723908

IF: 7.3

2021-09-30

Frontiers in Immunology

Abstract:Background Tumor infiltrating myeloid (TIM) cells constitute a vital element of the tumor microenvironment. The cell-type heterogeneity of TIM has yet to be fully investigated. Methods We used a time saving approach to generate a single-cell reference matrix, allowing quantification of cell-type proportions and cell-type-specific gene abundances in bulk RNA-seq data. Results Two distinct clusters, MSC1 and MSC2 (MSC subtype) were newly identified in lung adenocarcinoma (LUAD) patients, both significantly associated with overall survival and immune blockade therapy responses. Twenty myeloid cell types were detected. Thirteen of these had distinct enrichment patterns between MSC1 and MSC2. LAMP3+ dendritic cells, being a mature and transportable subtype of dendritic cell that may migrate to lymph nodes, were noted as associated with non-responsiveness to immunotargeted therapy. High infiltration level of IFIT3+ neutrophils was strongly related to the response to immune-targeted therapy and was seen to activate CD8+ T cells, partly through inflammasome activation. The infiltration levels of TIMP1+ macrophages and S100A8+ neutrophils were both significantly associated with poor prognosis. TIMP1+ macrophages were noted to recruit S100A8+ neutrophils via the CXCL5–CXCR2 axes and promote LUAD progression. Conclusion Altogether, we performed virtual microdissection of the bulk transcriptome at single-cell resolution and provided a promising TIM infiltration landscape that may shed new light on the development of immune therapy.

immunology
DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution

Lei Zhao,Xiaohong Wu,Junnian Zheng,Dong Dong

DOI: https://doi.org/10.1038/s41388-021-01657-0

IF: 8.756

2021-02-09

Oncogene

Abstract:Abstract DNA methylation plays a pivotal role in regulating cellular processes, and altered DNA methylation pattern is a general hallmark of cancer. However, DNA methylome in circulating tumor cells (CTCs) is still a mystery due to the lack of proper analytical techniques. We introduced an efficient workflow, LCM–μWGBS, which can efficiently profile the DNA methylation of microdissected CTC samples. LCM–μWGBS combines the laser capture microdissection (LCM)-based CTC capture method and whole-genome bisulfite sequencing in very small CTC population (μWGBS) to gain insight into the DNA methylation landscape of CTCs. We herein profiled the DNA methylome of CTCs from lung cancer patients. Deriving from a comprehensive analysis of CTC methylome, a unique “CTC DNA methylation signature” that is distinct from primary lung cancer tissues was identified. Further analysis showed that promoter hypermethylation of epithelial genes is a hallmark of stable epithelial–mesenchymal transition process. Moreover, it has been suggested that CTCs are endowed with a stemness-related feature during dissemination and metastasis. This work constitutes a unique DNA methylation analysis of CTCs at single base-pair resolution, which might facilitate to propose noninvasive CTC DNA methylation biomarkers contributing to clinical diagnosis.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
Comparative Analysis of Single-Cell Transcriptome Reveals Heterogeneity in the Tumor Microenvironment of Lung Adenocarcinoma and Brain Metastases.

Jialu Liang,Ruihao Liang,Kai Lei,Jing Huang,Huayue Lin,Minghui Wang

DOI: https://doi.org/10.1007/s12672-023-00784-2

2023-01-01

Discover Oncology

Abstract:PURPOSE:Solid tumors such as lung adenocarcinoma include not only the tumor cells but also the microenvironment in which the tumor cells continuously interact with each other. An in-depth understanding of the oncological features and tumor microenvironment (TME) of lung adenocarcinoma and brain metastases at the single-cell level could provide new therapeutic strategies for brain metastases from lung adenocarcinoma.METHODS:To solve this problem, we performed single-cell RNA sequencing (scRNA-seq) analysis on 15 lung adenocarcinoma samples and 10 brain metastasis samples.RESULTS:A total of 86,282 single cells were obtained and divided into 8 cell types, including epithelial cells, endothelial cells, fibroblasts, oligodendrocytes, T/NK cells, B cells, mast cells, and macrophages. In brain metastases, we found a significantly lower proportion of T/NK cells and mast cells, and more severe immune dysregulation. In addition, we found a subpopulation of macrophages with high expression of metastasis-promoting-related genes enriched in brain metastatic tissues. Moreover, in brain metastases, we found a significantly increased proportion of myofibroblastic cancer-associated fibroblasts (myCAFs) and a higher angiogenic capacity of endothelial cells. Epithelial cells in brain metastases were more malignant and underwent genomic reprogramming. Next, we found that DNA damage-inducible transcript 4 (DDIT4) expression was upregulated in epithelial cells in brain metastases and was associated with poor prognosis. Finally, we experimentally validated that the downregulation of DDIT4 inhibited the proliferation, migration, and invasion of lung cancer cells.CONCLUSIONS:This study depicts a single-cell atlas of lung adenocarcinoma and brain metastases by scRNA-seq and paves the way for the development of future therapeutic targets for brain metastases from lung cancer.
P2.01-001 Enrichment-Free, Rapid Metabolic Assay for Detection of Tumor Cells in Pleural Effusion and Pheripheral Blood: Topic: Analysis of Body Fluids in Cancer

Qihui Shi,Ying Tang,Zhuo Wang,Ziming Li,Wei,Shun Lu

DOI: https://doi.org/10.1016/j.jtho.2016.11.1053

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:Current methods for circulating tumor cell (CTC) detection are mostly include an enrichment step and the subsequent immunostaining-based identification of CTCs by epithelial and leukocytes markers. These methods are limited by loss and damage of CTCs during the enrichment and fail to determine the malignancy and drug targets of putative CTCs. We describe an enrichment-free, metabolic-based assay for rapid detection of tumor cells in the pleural effusion and peripheral blood samples. All nucleated cells are plated on microwell chips that contain 200,000 addressable microwells. These cells are labeled with a fluorescent anti-CD45 antibody (leukocyte marker), a fluorescent glucose analog (2-NBDG) and a dead cell marker (EthD-1). The microwell chips are imaged by a computerized high-speed fluorescent microscope in three colors and the bright filed. A computation algorithm analyzes the images and identify candidate tumor cells that are viable, CD45 negative, and exhibit high glucose uptake (EthD-1-/CD45-/2-NBDGhigh). A micromanipultor is then utilized to retrieve single tumor cells based on recorded addresses for single-cell sequencing. EthD-1-/CD45-/2-NBDG>100 cells are identified as candidate tumor cells. Single-cell sequencing based on a small panel of driver oncogenes (EGFR, KRAS, PIK3CA) shows that >60% of candidate tumor cells are true tumor cells harboring mutations in the panel. Single-cell whole exome sequencing results show all candidate tumor cells have high mutation frequency in dirver oncogenece and tumor suppressors from Qiagen's Human Lung Cancer Panel. Meanwhile, CD45-/EthD-1-/2-NBDG>100 tumor cells show heterogenieity in cytokeratin (CK) expression, and only ∼40% of these tumor cells are found CK positive. We have developed a simple and functional-based method to rapidly identify tumor cells with high glucose uptake in the clinical liquid samples without enrichment. These tumor cells are addressable, enabling single-cell manipulation and sequencing. Clinical feasibility of this assay has been established by testing samples from a cohort of patients.
Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets

Hai-Yan Tu,Yang-Si Li,Xiao-Yan Bai,Yue-Li Sun,Ming-Ying Zheng,E-E Ke,Ri-Qiang Liao,Ben-Yuan Jiang,Jia-Xin Lin,Jie Huang,Bing-Fei Xu,Jin-Ji Yang,Xu-Chao Zhang,Qing Zhou,Bin-Chao Wang,Hua-Jun Chen,Xiaoling Tong,Ruoying Yu,Xue Wu,Dongqin Zhu,Yi-Long Wu

DOI: https://doi.org/10.1016/j.cllc.2021.09.002

IF: 4.84

2022-03-01

Clinical Lung Cancer

Abstract:Background: Pleural effusion(PE) has been one of the promising sources of liquid biopsy in advanced lung cancer patients. However, its clinical utility is not widely accepted due to the lack of full estimation of its potential versus routine clinical samples.Method: A total of 164 advanced lung cancer patients were enrolled with 164 matched tumor tissue and PE-cfDNA, 153 accompanied plasma and 63 PE-sDNA.Result: PE-cfDNA displayed significantly higher median mutant allele frequency and an overall mutation concordance rate of 65% to tissue, which was higher than PE-sDNA (43%) and plasma-cfDNA (43%). The discrepancies between PE-cfDNA and tumor tissue were high in several genes, including SMARCA4, PIK3CA, ERBB2, KM T2A, ALK and NF1. For clinically actionable mutations, the concordance rate between PE-cfDNA and tumor tissue is 87%. Eleven patients were identified with actionable mutations in PE-cfDNA and four patients benefited from PE-cfDNA-guided targeted. Meanwhile, PE-cfDNA recapitulated mutations of diverse tissue origins and provided more mutational information under the circumstance that tumor tissue or tumor tissue of different origins were unavailable. The combination of tumor tissue and PE-cfDNA profiling increased positive detection rates of patients compared to tumor tissue alone. Our finding highlighted the importance of PE-cfDNA in the optimal selection of patients for targeted therapy.Conclusion: The PE-cfDNA-based liquid biopsy displays better performance in the characterization of gene alterations than PE-sDNA and plasma-cfDNA. PE-cfDNA together with tumor tissue profiling optimizes comprehensively genomic profiling of lung cancer patients, which might be important for selecting patients for better treatment management.

oncology
Paralytic shellfish toxin concentration and cell density changes in Pyrodinium bahamense -Noctiluca scintillans feeding experiments.

R. Azanza,L. Cruz,F. Cariño,A. Blanco,V. Butardo

DOI: https://doi.org/10.1016/j.toxicon.2009.09.017

IF: 3.035

2010-05-01

Toxicon

Abstract:
MA 20.13 Etdna: Tumor-Derived DNA from Pleural Effusion Supernatant As a Promising Source for NGS-Based Mutation Profiling in Lung Cancer

L. Tong,N. Ding,J. Li,X. Wang,Y. Zhang,X. Xu,M. Ye,C. Li,H. Zhang,X. Zhu,Z. Zhu,J. Zhou,J. She,Y. W. Shao,X. Zhang,H. Bao,S. Xu,Q. Hong,C. Bai,J. Hu

DOI: https://doi.org/10.1016/j.jtho.2017.09.652

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:Mutation profiling of circulating tumor DNA (ctDNA) and pleural effusion sediment containing tumor cells (ETCs) were commonly applied in clinical practice. Several studies suggested that tumor-derived DNA from pleural effusion supernatant (etDNA) might be a better candidate for detecting gene alterations in lung cancer. However, little is known regarding the abundance and diversity of tumor DNA acquired among different types of liquid biopsy. We performed targeted next generation sequencing (NGS)-based genetic profiling on tumor tissue, pleural effusion (etDNA & ETCs) and contemporaneous ctDNA from 63 lung cancer patients (58 adenocarcinoma, 2 adenosquamous carcinoma, 2 SCLC, 1 neuroendocrine carcinoma), among which 28 patients had paired tumor tissue samples. Genomic DNA from whole blood of each patient was used for germline control. Driver mutation and rearrangement profiling was validated using ARMS-PCR, FISH, or Ventana IHC assay in tumor tissue as golden standard. We identified tumor-specific mutations in 98%, 89%, 86%, and 100% of patients in their etDNAs, ETCs, ctDNAs and tumor tissues, respectively (p<0.01). etDNAs showed a significantly higher tumor-specific mutation number per patient (Median: 5) compared to ETCs and plasma ctDNAs (Median of 3 for both), while the median number in tumor tissues is 4 per patient. The detection sensitivity for EGFR mutations in etDNAs is 95%, higher than that in ETCs and ctDNAs (89% and 63%, respectively). Two patients detected ALK fusion in tumor tissue were also positive in etDNA, only one patient was positive in ETCs and ctDNA, respectively. A total of 298 genetic alterations, including point mutations, indels, copy number variations (CNVs) and gene fusions, were identified in etDNAs from all the patients. However, only 74% and 57% of these alterations were detected in contemporaneous ETCs and ctDNA samples, with CNVs having the lowest detection sensitivity as 49% and 11%, especially in lung cancer patients without extrathoracic metastasis, as none of the CNVs detected in etDNAs were captured in plasma ctDNAs of these patients. Furthermore, driver mutations and rearrangements in etDNA showed a strong correlation to targeted therapy efficacy. This study demonstrated that etDNA had significantly higher tumor-specific mutation detection rate and sensitivity compared to ETCs and ctDNA. etDNA from supernatant of pleural effusion is a promising source for genetic testing to guide treatment-decision making in lung cancer. This study is funded by Shanghai Science and Technology Program (15ZR1406400).
Signatures of Malignant Cells and Novel Therapeutic Targets Revealed by Single‐cell Sequencing in Lung Adenocarcinoma

Jiaqi Liang,Zhencong Chen,Yiwei Huang,Guoshu Bi,Yunyi Bian,Xing Jin,Huan Zhang,Qihai Sui,Cheng Zhan,Qun Wang

DOI: https://doi.org/10.1002/cam4.4547

IF: 4.711

2022-01-01

Cancer Medicine

Abstract:Background Single-cell transcriptomics has been used to investigate various tumors to elucidate the molecular distinction of all cell type compositions of a complex mix. Aims This study aimed to investigate malignant-cell-specific genes to explore diagnostic and therapeutic biomarkers using single-cell transcriptomic data of lung adenocarcinoma. Materials & Methods 10X single-cell RNA-seq data of fourteen patients with lung adenocarcinoma were analyzed. Genes that expressed differentially and those with higher confidence to distinguish tumor cells from normal cells were picked out using the ROC curves. The LASSO regression method was used to select most markedly correlated genes to predict the malignancy of every single cell within a model. We also conducted further experiments to determine their roles in lung cancer in vitro. Results Twenty two thousand four hundred and ninety one tumor and 181 666 normal single cells were analyzed where 369 genes were found to be specifically expressed in single malignant cells. Seventy of them, encoding secreted or membrane-bound proteins, showed involvement in cell-to-cell communications in tumor biology. KRT18 and the other six genes were identified as predictors to distinguish single malignant cells and were integrated to construct an accurate (96.1%) predicting model. Notably, IRX2, SPINK13, and CAPN8 outperformed the other four genes. Further experiments confirmed the upregulation of them in lung adenocarcinoma at both tissue and cell levels. Proliferative capacities of lung adenocarcinoma cells were attenuated by knocking-down of either of them. However, targeting CAPN8, IRX2, or SPINK13 hardly exerted a cytotoxic effect on these cells. Discussion Apart from the current model, similar tools were still warranted using single-cell RNA-seq data of more types of tumors. The three genes identified as potential therapeutic targets in the present study still need to be validated in more in lung cancer. Conclusion Our model can aid the analyses of single-cell sequencing data. CAPN8, IRX2, and SPINK13 may serve as novel targets of targeted and immune-based therapies in lung adenocarcinoma.
Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer

Say Li Kong,Xingliang Liu,Swee Jin Tan,Joyce A. Tai,Ler Yee Phua,Huay Mei Poh,Trifanny Yeo,Yong Wei Chua,Yu Xuan Haw,Wen Huan Ling,Raymond Chee Hui Ng,Tira J. Tan,Kiley Wei Jen Loh,Daniel Shao-Weng Tan,Quan Sing Ng,Mei Kim Ang,Chee Keong Toh,Yi Fang Lee,Chwee Teck Lim,Tony Kiat Hon Lim,Axel M. Hillmer,Yoon Sim Yap,Wan-Teck Lim

DOI: https://doi.org/10.3389/fonc.2021.698551

IF: 4.7

2021-07-16

Frontiers in Oncology

Abstract:Introduction Circulating tumor cells (CTCs) and cell-free tumor DNA (ctDNA) are tumor components present in circulation. Due to the limited access to both CTC enrichment platforms and ctDNA sequencing in most laboratories, they are rarely analyzed together. Methods Concurrent isolation of ctDNA and single CTCs were isolated from lung cancer and breast cancer patients using the combination of size-based and CD45-negative selection method via DropCell platform. We performed targeted amplicon sequencing to evaluate the genomic heterogeneity of CTCs and ctDNA in lung cancer and breast cancer patients. Results Higher degrees of genomic heterogeneity were observed in CTCs as compared to ctDNA. Several shared alterations present in CTCs and ctDNA were undetected in the primary tumor, highlighting the intra-tumoral heterogeneity of tumor components that were shed into systemic circulation. Accordingly, CTCs and ctDNA displayed higher degree of concordance with the metastatic tumor than the primary tumor. The alterations detected in circulation correlated with worse survival outcome for both lung and breast cancer patients emphasizing the impact of the metastatic phenotype. Notably, evolving genetic signatures were detected in the CTCs and ctDNA samples during the course of treatment and disease progression. Conclusions A standardized sample processing and data analysis workflow for concurrent analysis of CTCs and ctDNA successfully dissected the heterogeneity of metastatic tumor in circulation as well as the progressive genomic changes that may potentially guide the selection of appropriate therapy against evolving tumor clonality.

oncology
Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single‐cell transcriptome analysis

Haoyu Ruan,Yihang Zhou,Jie Shen,Yue Zhai,Ying Xu,Linyu Pi,Ruofan Huang,Kun Chen,Xiangyu Li,Weizhe Ma,Zhiyuan Wu,Xuan Deng,Xu Wang,Chao Zhang,Ming Guan

DOI: https://doi.org/10.1002/ctm2.246

IF: 8.554

2020-12-01

Clinical and Translational Medicine

Abstract:BACKGROUND: Brain metastases explain the majority of mortality associated with lung cancer, which is the leading cause of cancer death. Cytology analysis of the cerebrospinal fluid (CSF) remains the diagnostic gold standard, however, the circulating tumor cells (CTCs) in CSF (CSF-CTCs) are not well defined at the molecular and transcriptome levels.METHODS: We established an effective CSF-CTCs collection procedure and isolated individual CSF cells from five lung adenocarcinoma leptomeningeal metastases (LUAD-LM) patients and three controls. Three thousand seven hundred ninety-two single-cell transcriptomes were sequenced, and single-cell RNA sequencing (scRNA-seq) gene expression analysis was used to perform a comprehensive characterization of CSF cells.RESULTS: Through clustering and expression analysis, we defined CSF-CTCs at the transcriptome level based on epithelial markers, proliferation markers, and genes with lung origin. The metastatic-CTC signature genes are enriched for metabolic pathway and cell adhesion molecule categories, which are crucial for the survival and metastases of tumor cells. We discovered substantial heterogeneity in patient CSF-CTCs. We quantified the degree of heterogeneity and found significantly greater among-patient heterogeneity compared to among-cell heterogeneity within a patient. This observation could be explained by spatial heterogeneity of metastatic sites, cell-cycle gene, and cancer-testis antigen (CTA) expression profiles as well as the proportion of CTCs displaying mesenchymal and cancer stem cell properties. In addition, our CSF-CTCs transcriptome profiling allowed us to determine the biomarkers during the progression of an LM patient with cancer of unknown primary site (CUP).CONCLUSIONS: Our results will provide candidate genes for an RNA-based digital detection of CSF-CTCs from LUAD-LM and CUP-LM cases, and shed light on the therapy and mechanism of LUAD-LM.

oncology,medicine, research & experimental
A fine-grained cell type deconvolution of bulk transcriptome from single-cell RNA-seq data reveals myeloid cells heterogeneity in lung adenocarcinomas

Hao Wu,Jiale Qin,Qiang Zhao,Lu Lu,Dante Neculai,Chen Li

DOI: https://doi.org/10.21203/rs.3.rs-261065/v1

2021-01-01

Abstract:Abstract Background Tumor infiltrating myeloid cells (TIM) constitute a vital element of the tumor microenvironment. The cell-type heterogeneity of TIM has yet to be fully investigated. Methods We used a time saving approach to generate a single-cell reference matrix, allowing quantification of cell-type proportions and cell-type-specific gene abundances in bulk RNA-seq data. Results Two distinct clusters, MSC1 and MSC2 (MSC subtype) were newly identified in lung adenocarcinoma (LUAD) patients, both significantly associated with overall survival and immune blockade therapy responses. Twenty myeloid cell types were detected. Thirteen of these had distinct enrichment patterns between MSC1 and MSC2. LAMP3 + dendritic cells, being a mature and transportable subtype of dendritic cell which may migrate to lymph nodes, were noted as associated with non-responsiveness to immunotargeted therapy. High infiltration level of IFIT3 + neutrophils was strongly related to the response to immune targeted therapy and was seen to activate CD8 + T cells, partly through inflammasome activation. The infiltration levels of TIMP1 + macrophages and S100A8 + neutrophils were both significantly associated with poor prognosis. TIMP1 + macrophages were noted to recruit S100A8 + neutrophils via the CXCL5-CXCR2 axes and promote LUAD progression. Conclusion Altogether, we performed virtual micro-dissection of the bulk transcriptome at single-cell resolution and provided a promising TIM infiltration landscape that may shed new light on the development of immune therapy.
Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma

Tianyu Fan,Jian Lu,Delei Niu,Yue Zhang,Bin Wang,Bei Zhang,Zugui Zhang,Xinjiai He,Nan Peng,Biao Li,Huilong Fang,Zheng Gong,Li Zhang

DOI: https://doi.org/10.3389/fimmu.2022.1046121

IF: 7.3

2022-11-22

Frontiers in Immunology

Abstract:Lung adenocarcinoma (LUAD) is the most common type of lung cancer and the leading cause of cancer incidence and mortality worldwide. Despite the improvement of traditional and immunological therapies, the clinical outcome of LUAD is still far from satisfactory. Patients given the same treatment regimen had different responses and clinical outcomes due to the heterogeneity of LUAD. How to identify the targets based on heterogeneity analysis is crucial for treatment strategies. Recently, the single-cell RNA-sequencing (scRNA-seq) technology has been used to investigate the tumor microenvironment (TME) based on cell-specific changes and shows prominently valuable for biomarker prediction. In this study, we systematically analyzed a meta-dataset from the multiple LUAD scRNA-seq datasets in LUAD, identified 15 main types of cells and 57 cell subgroups, and revealed a series of potential biomarkers in M2b, exhausted CD8 + T, endothelial cells, fibroblast, and metabolic patterns in TME, which further validated with immunofluorescence in clinical cohorts of LUAD. In the prognosis analysis, M0 macrophage and T cell activation were shown correlated to a better prognosis ( p <0.05). Briefly, our study provided insights into the heterogeneity of LUAD and assisted in novel therapeutic strategies for clinical outcome improvement.

immunology
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

Avanish Mishra,Shih-Bo Huang,Taronish Dubash,Risa Burr,Jon F. Edd,Ben S. Wittner,Quinn E. Cunneely,Victor R. Putaturo,Akansha Deshpande,Ezgi Antmen,Kaustav A. Gopinathan,Keisuke Otani,Yoshiyuki Miyazawa,Ji Eun Kwak,Sara Y. Guay,Justin Kelly,John Walsh,Linda Nieman,Isabella Galler,PuiYee Chan,Michael S. Lawrence,Ryan J. Sullivan,Aditya Bardia,Douglas S. Micalizzi,Lecia V. Sequist,Richard J. Lee,Joseph W. Franses,David T. Ting,Patricia A. R. Brunker,Shyamala Maheswaran,David T. Miyamoto,Daniel A. Haber,Mehmet Toner

DOI: https://doi.org/10.1101/2024.03.13.583573

2024-03-14

Abstract:Circulating Tumor Cells (CTCs), interrogated by sampling blood from patients with cancer, contain multiple analytes, including intact RNA, high molecular weight DNA, proteins, and metabolic markers. However, the clinical utility of tumor cell-based liquid biopsy has been limited since CTCs are very rare, and current technologies cannot process the blood volumes required to isolate a sufficient number of tumor cells for in-depth assays. We previously described a high-throughput microfluidic prototype utilizing high-flow channels and amplification of cell sorting forces through magnetic lenses. Here, we apply this technology to analyze patient-derived leukapheresis products, interrogating a mean blood volume of 5.83 liters from patients with metastatic cancer, with a median of 2,799 CTCs purified per patient. Isolation of many CTCs from individual patients enables characterization of their morphological and molecular heterogeneity, including cell and nuclear size and RNA expression. It also allows robust detection of gene copy number variation, a definitive cancer marker with potential diagnostic applications. High-volume microfluidic enrichment of CTCs constitutes a new dimension in liquid biopsies.

Bioengineering
High-throughput Screening of Rare Metabolically Active Tumor Cells in Pleural Effusion and Peripheral Blood of Lung Cancer Patients

Yin Tang,Zhuo Wang,Ziming Li,Jungwoo Kim,Yuliang Deng,Yan Li,James R Heath,Wei,Shun Lu,Qihui Shi

DOI: https://doi.org/10.1073/pnas.1612229114

2017-01-01

Abstract:Significance Identification of cancer cells in the pleural effusions of lung cancer patients is an important clinical diagnosis to verify the malignant pleural involvement. Elevated glucose uptake is a hallmark of cancer cells and has been used in positron-emission tomography to detect malignant tumors in vivo. We hypothesize that cells with enhanced glucose uptake and without expression of leukocyte markers in pleural effusion or peripheral blood samples are highly likely to be malignant cells that can be confirmed via single-cell sequencing. To this end, a high-throughput metabolic-based assay is developed for rapid detection of rare metabolically active tumor cells in pleural effusion, enabling sensitive diagnosis of malignant pleural effusion in the clinic that is associated with metastatic malignancies. Malignant pleural effusion (MPE), the presence of malignant cells in pleural fluid, is often the first sign of many cancers and occurs in patients with metastatic malignancies. Accurate detection of tumor cells in pleural fluid is crucial because the presence of MPE denotes an advanced stage of disease and directs a switch in clinical managements. Cytology, as a traditional diagnostic tool, has limited sensitivity especially when tumor cells are not abundant, and may be confounded by reactive mesothelial cells in the pleural fluid. We describe a highly sensitive approach for rapid detection of metabolically active tumor cells in MPE via exploiting the altered glucose metabolism of tumor cells relative to benign cells. Metabolically active tumor cells with high glucose uptake, as evaluated by a fluorescent glucose analog (2-NBDG), are identified by high-throughput fluorescence screening within a chip containing 200,000 addressable microwells and collected for malignancy confirmation via single-cell sequencing. We demonstrate the utility of this approach through analyzing MPE from a cohort of lung cancer patients. Most candidate tumor cells identified are confirmed to harbor the same driver oncogenes as their primary lesions. In some patients, emergence of secondary mutations that mediate acquired resistance to ongoing targeted therapies is also detected before resistance is manifested in the clinical imaging. The detection scheme can be extended to analyze peripheral blood samples. Our approach may serve as a valuable complement to cytology in MPE diagnosis, helping identify the driver oncogenes and resistance-leading mutations for targeted therapies.
Single‐cell RNA sequencing captures patient‐level heterogeneity and associated molecular phenotypes in breast cancer pleural effusions

Holly J. Whitfield,Jean Berthelet,Stefano Mangiola,Caroline Bell,Robin L. Anderson,Bhupinder Pal,Belinda Yeo,Anthony T. Papenfuss,Delphine Merino,Melissa J. Davis

DOI: https://doi.org/10.1002/ctm2.1356

IF: 8.554

2023-09-12

Clinical and Translational Medicine

Abstract:Malignant pleural effusions (MPEs) are common complications of advanced breast cancer. However, their cellular composition is still unclear. Here we generated a novel single‐cell dataset to explore the heterogeneity of these valuable clinical samples, including cancer cells and normal cells from the tumour microenvironment. Background Malignant pleural effusions (MPEs) are a common complication of advanced cancers, particularly those adjacent to the pleura, such as lung and breast cancer. The pathophysiology of MPE formation remains poorly understood, and although MPEs are routinely used for the diagnosis of breast cancer patients, their composition and biology are poorly understood. It is difficult to distinguish invading malignant cells from resident mesothelial cells and to identify the directionality of interactions between these populations in the pleura. There is a need to characterize the phenotypic diversity of breast cancer cell populations in the pleural microenvironment, and investigate how this varies across patients. Methods Here, we used single‐cell RNA‐sequencing to study the heterogeneity of 10 MPEs from seven metastatic breast cancer patients, including three Miltenyi‐enriched samples using a negative selection approach. This dataset of almost 65 000 cells was analysed using integrative approaches to compare heterogeneous cell populations and phenotypes. Results We identified substantial inter‐patient heterogeneity in the composition of cell types (including malignant, mesothelial and immune cell populations), in expression of subtype‐specific gene signatures and in copy number aberration patterns, that captured variability across breast cancer cell populations. Within individual MPEs, we distinguished mesothelial cell populations from malignant cells using key markers, the presence of breast cancer subtype expression patterns and copy number aberration patterns. We also identified pleural mesothelial cells expressing a cancer‐associated fibroblast‐like transcriptomic program that may support cancer growth. Conclusions Our dataset presents the first unbiased assessment of breast cancer‐associated MPEs at a single cell resolution, providing the community with a valuable resource for the study of MPEs. Our work highlights the molecular and cellular diversity captured in MPEs and motivates the potential use of these clinically relevant biopsies in the development of targeted therapeutics for patients with advanced breast cancer.

oncology,medicine, research & experimental

Granulomatous eosinophilic epicarditis in the newborn. Report of three cases.

[Identification and Single-Cell Sequencing Analysis of Rare Tumor Cells in Malignant Pleural Effusion of Lung Cancer Patients].

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics

Single-cell analysis of diverse immune phenotypes in malignant pleural effusion

Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor

Microdissection of the Bulk Transcriptome at Single-Cell Resolution Reveals Clinical Significance and Myeloid Cells Heterogeneity in Lung Adenocarcinoma

DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution

Comparative Analysis of Single-Cell Transcriptome Reveals Heterogeneity in the Tumor Microenvironment of Lung Adenocarcinoma and Brain Metastases.

P2.01-001 Enrichment-Free, Rapid Metabolic Assay for Detection of Tumor Cells in Pleural Effusion and Pheripheral Blood: Topic: Analysis of Body Fluids in Cancer

Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets

Paralytic shellfish toxin concentration and cell density changes in Pyrodinium bahamense -Noctiluca scintillans feeding experiments.

MA 20.13 Etdna: Tumor-Derived DNA from Pleural Effusion Supernatant As a Promising Source for NGS-Based Mutation Profiling in Lung Cancer

Signatures of Malignant Cells and Novel Therapeutic Targets Revealed by Single‐cell Sequencing in Lung Adenocarcinoma

Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer

Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single‐cell transcriptome analysis

A fine-grained cell type deconvolution of bulk transcriptome from single-cell RNA-seq data reveals myeloid cells heterogeneity in lung adenocarcinomas

Immune and non-immune cell subtypes identify novel targets for prognostic and therapeutic strategy: A study based on intratumoral heterogenicity analysis of multicenter scRNA-seq datasets in lung adenocarcinoma

Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product

High-throughput Screening of Rare Metabolically Active Tumor Cells in Pleural Effusion and Peripheral Blood of Lung Cancer Patients

Single‐cell RNA sequencing captures patient‐level heterogeneity and associated molecular phenotypes in breast cancer pleural effusions